There have been significant challenges in targeting this pathway clinically, but the successful FDA approvals of the PI3K inhibitors alpelisib and inavolisib and the AKT inhibitor capivasertib for PI3K-pathway-mutant breast cancer are a major step in the right direction (Table 1). This evidence concerns the gene AKT1 and breast cancer.